Azaran on 1/5/2022 at 23:26
(
https://www.yorkregion.com/news-story/10616735-can-t-shake-omicron-symptoms-you-re-not-alone/) Looks like Omicron also causes long covid
Quote:
Dr. Kashif Pirzada, a Toronto emergency physician, said he's seen more people coming in with persistent symptoms after Omicron — most commonly difficulty breathing, and a cough, but also some cognitive issues — than in other waves.
Often their family doctors have already tried everything they can. “I've had patients leaving in tears when we tell them, there's not much we can do for you,” he said.
He and his colleagues run tests and send them to a respirologist, neurologist or cardiologist, depending on their specific problems, but the wait times can be long and there's no guarantee they'll have answers.
“I think that the enormous load that these long COVID patients are going to be putting on health services will increase wait times for everybody,” he added.
In B.C., Dr. Jane McKay, the medical lead for that province's post COVID-19 interdisciplinary clinical care network, said they have actually seen fewer people coming in lately to their five clinics. Their “referral volume is dramatically down” and there's no longer anyone on the waiting list.
This could be because symptoms are not as bad with Omicron, or because family doctors are getting more comfortable navigating their patients though this process, said McKay.
demagogue on 2/5/2022 at 02:06
This is only anecdotal of course, but practically the very day omicron first peaked in Tokyo I got my characteristic long covid symptoms back (the arrhythmia & head faints in particular; they're really specific). Fortunately it only lasted for about 2 days and disappeared as quickly as it came on and I haven't been bothered since. Since it's still really hard to get tested here and I never show the respiratory side of it, I still can't officially say it was actually covid related; it's just a very familiar coincidence.
Responding to the end of that blurb you quoted, I don't know what I would have done if it had persisted. Because of the bad experience I had the first round of it, I probably wouldn't even bother going to the hospital or family clinic because both of them rejected my narrative so completely & left me so dejected that I'd have no incentive to go through that again. I suspect that's closer to the why the referral rate is down, but I could be wrong and/or misunderstanding what they're actually measuring and would defer to somebody that's researched it more.
Azaran on 2/5/2022 at 22:25
Quote Posted by demagogue
This is only anecdotal of course, but practically the very day omicron first peaked in Tokyo I got my characteristic long covid symptoms back (the arrhythmia & head faints in particular; they're really specific). Fortunately it only lasted for about 2 days and disappeared as quickly as it came on and I haven't been bothered since. Since it's still really hard to get tested here and I never show the respiratory side of it, I still can't officially say it was actually covid related; it's just a very familiar coincidence.
Could have been a resurgence of your original one, but who knows.
On the plus side, looks like this (
https://globalnews.ca/news/8766853/paxlovid-long-covid/) new antiviral is resolving at least some long covid cases
Quote:
In one of the case reports, published as a preprint ahead of peer review, a previously healthy and vaccinated 47-year-old woman became infected with COVID in the summer of 2021. Most of her acute symptoms dissipated within 48 hours, but she continued to have severe fatigue, brain fog, exhaustion after exercise, insomnia, racing heartbeat and body aches severe enough that she could no longer work.
About six months after her initial infection, she was reinfected, likely with COVID, and many of her acute symptoms also returned. Her doctor prescribed a five-day course of Paxlovid.
On day 3, she noticed a rapid improvement of long COVID symptoms. “She's back to normal,” said Dr. Linda Geng, co-director of Stanford Health Care's long COVID clinic and author of the case report posted on Research Square.
In the second case, Lavanya Visvabharathy, 37, an immunologist working at Northwestern Medicine's long COVID clinic, was infected in December 2021. Her initial symptoms were mild, but she later experienced chronic fatigue, headaches and sleep disturbances for four months after infection. She also kept testing positive on rapid antigen tests, a sign of viral persistence.
Visvabharathy was aware of the NIH study and the Stanford case, and decided to try Paxlovid to see if it could clear any lingering virus. Toward the end of the five-day course, her fatigue and insomnia had improved, and her headaches were less frequent. Two weeks after treatment ended, her fatigue was gone.
“That's 100 per cent fixed,” she said.
Cipheron on 3/5/2022 at 08:26
Quote Posted by Azaran
On the plus side, looks like this Paxlovid is resolving at least some long covid cases
Wow that definitely looks promising. However I wonder if it's going to be a case where we give it to people because it just works, then work out exactly why it's working later on, and whether it could it be a candidate treatment for people with other similar chronic illnesses, such as chronic fatigue syndrome.
Azaran on 6/5/2022 at 12:14
It's out
(
https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/selfreportedlongcovidafterinfectionwiththeomicronvariant/6may2022#prevalence-of-self-reported-long-covid-between-variants)
Quote:
The odds of reporting long COVID symptoms four to eight weeks after a first coronavirus (COVID-19) infection were 49.7% lower in infections compatible with the Omicron BA.1 variant than those compatible with the Delta variant among adults who were double-vaccinated when infected; this was after adjusting for socio-demographic characteristics.
However, there was no statistical evidence of a difference in risk between first infections compatible with the Delta and Omicron BA.1 variants among triple-vaccinated adults; the socio-demographically adjusted prevalence of self-reported long COVID was 8.5% for Delta and 8.0% for Omicron BA.1.
There was also no statistical evidence of a difference in risk between first infections compatible with the Delta and Omicron BA.2 variants among triple-vaccinated adults; the socio-demographically adjusted prevalence of self-reported long COVID was 7.4% for Delta and 9.1% for Omicron BA.2.
The odds of reporting long COVID symptoms four to eight weeks after a first COVID-19 infection were 21.8% higher after an infection compatible with Omicron BA.2 than Omicron BA.1 among adults who were triple-vaccinated when infected; this was after adjusting for socio-demographic characteristics and time since last COVID-19 vaccination.
The results above relate to long COVID symptoms of any severity; similar findings were obtained when focussing on symptoms that limited daily activities, except there was no statistical evidence of a difference in the likelihood of activity-limiting long COVID between the Omicron BA.1 and BA.2 variants.
...
Among double-vaccinated, adult study participants, the socio-demographically adjusted prevalence of self-reported long COVID four to eight weeks after a first coronavirus (COVID-19) infection compatible with the Delta variant was 15.9%. This is compared with 8.7% for infections compatible with the Omicron BA.1 variant (Figure 1, first panel).
Among triple-vaccinated adults, there was no statistical evidence of a difference in the adjusted prevalence of self-reported long COVID between first infections compatible with the Delta variant and those compatible with either Omicron BA.1 (Figure 1, second panel) or Omicron BA.2 (Figure 1, third panel). However, adjusted prevalence was higher for infections compatible with Omicron BA.2 (9.3%) than it was for those compatible with Omicron BA.1 (7.8%) (Figure 1, fourth panel).
Azaran on 20/5/2022 at 14:22
(
https://www.news-medical.net/news/20220103/Echinacea-a-potent-antiviral-against-SARS-CoV-2.aspx) Good news, Echinacea is helpful against Covid
Quote:
A clinical study carried out from November 2020 until May 2021 was also included in this review to confirm the applicability of the antiviral benefits of Echinacea. This clinical study investigated the effect of an Echinacea purpurea preparation in dosages within the range of 2,400 mg to 4,000 mg extract per day in 120 adults over five months.
In the Echinacea and control groups, five and 14 samples tested positive for SARS-CoV-2. During acute SARS-CoV-2 episodes, Echinacea treatment significantly reduced the overall virus load by about 99%, the time to virus clearance by 4.8 days, and fever days to 1 day versus 11 days as compared to the control group.
faetal on 27/5/2022 at 10:21
Those are very small samples.
Thor on 27/5/2022 at 12:11
People still talk about this even after billy boy himself called this "kind of like a flu" huh? Will see what the world government has in store for us for the autumn, but the money pox nonsense looks like a dry run at most.
